Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors [Yahoo! Finance]
Dyne Therapeutics: 2026 Catalysts Point To Further Upside [Seeking Alpha]
Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $17.00 to $16.00. They now have a "neutral" rating on the stock.
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference